THE UNITED LABORATORIES INTERNATIONAL HOLDINGS LIMITED

The United Laboratories International Holdings Limited

3933

KYG8813K1085

Pharmaceuticals

Delayed Hong Kong S.E. Other stock markets 10:48:00 2024-04-17 pm EDT			5-day change	1st Jan Change
9.59 ^HKD	0.00%		-3.23%	+36.80%

Mar. 27	The United Laboratories International Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 27	The United Laboratories International's 2023 Profit Rises on Higher Revenue	MT

The United Laboratories International Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2019

March 30, 2020 at 06:15 pm EDT

The Board of The United Laboratories International Holdings Limited proposed a final dividend of 7 RMB cents per share for the year ended 31 December 2019.

Latest news about The United Laboratories International Holdings Limited

The United Laboratories International Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
The United Laboratories International's 2023 Profit Rises on Higher Revenue	Mar. 26	MT
The United Laboratories International Holdings Limited Recommends Payment of Final Dividend for the Year Ended 31 December 2023	Mar. 26	CI
The United Laboratories International Holdings Limited Recommends Payment of Special Dividend for the Year Ended 31 December 2023	Mar. 26	CI
The United Laboratories International Forecasts Profit Surge in 2023	Mar. 14	MT
The United Laboratories International Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023	Mar. 14	CI
United Laboratories Postpones EGM Due to Bad Weather	23-10-09	MT
United Laboratories Subsidiary Gets US FDA Nod for Injectable for Diabetes; Shares Rise 8%	23-09-26	MT
The United Laboratories International Holdings Limited Announces FDA Approval of IND for UBT251 Injection	23-09-26	CI
The United Laboratories International Holdings Limited Announces Interim Dividend for Six Months Ended 30 June 2023, Payable on 11 October 2023	23-09-21	CI
United Laboratories Controlling Shareholder to Sell 64 Million Shares	23-09-19	MT
United Laboratories International Unit Gets Regulatory Nod to Conduct Trial on TUL01101 Tablets	23-09-11	MT
Chinese Regulator Allows Clinical Trial of United Laboratories' Fatty-Liver Drug	23-09-08	MT
The United Laboratories International Holdings Limited Announces Application for the Clinical Trial of Class 1 Innovative New Drug UBT251 Injection	23-09-08	CI
United Laboratories International Says Two Products Pass Consistency Evaluation	23-09-07	MT
China Greenlights United Laboratories' Clinical Trial for Obesity Injection; Shares Rise 4%	23-09-03	MT
The United Laboratories International Holdings Limited Announces Approval for Clinical Trial of Ubt251 Injection on Indication of Overweight or Obesity	23-09-03	CI
The United Laboratories International Holdings Limited Announces Ordinary Interim (Semi-Annual) Dividend for Six Months Ended 30 June 2023	23-08-30	CI
United Laboratories' H1 Profit Doubles; Shares Fall 4%	23-08-30	MT
The United Laboratories International Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
The United Laboratories International Holdings Limited Announces Approval of the New Drug, TUL12101	23-08-29	CI
Chinese Drug Regulator Accepts United Laboratories International Unit's Application for Marketing of Diabetes Drug; Shares Up 3%	23-08-24	MT
United Laboratories Expects H1 Profit to Nearly Double; Shares Surge 10%	23-08-16	MT
The United Laboratories International Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2023	23-08-16	CI
United Laboratories International Holdings Unit's Injection for Pneumonia Passes China's Consistency Evaluation	23-07-27	MT

Chart The United Laboratories International Holdings Limited

Duration

Period

Chart The United Laboratories International Holdings Limited

More charts

The United Laboratories International Holdings Limited is an investment holding company principally engaged in the sales of intermediate products, bulk medicine and finished products. The Company operates its business through three segments. The Intermediate Products segment is engaged in the sale of intermediate products. The Bulk Medicine segment is engaged in the sale of bulk medicine. The Finished Products segment is engaged in the sale of antibiotics finished products, non-antibiotics finished products and capsule casings. Through its subsidiaries, the Company is also engaged in the production and sale of organic fertilizer.

Sector

Pharmaceuticals

Calendar

2024-06-16 - Ex-dividend day for extraordinary dividend

More about the company

Income Statement Evolution

More financial data

Ratings for The United Laboratories International Holdings Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.59 HKD

Average target price

12.12 HKD

Spread / Average Target

+26.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
THE UNITED LABORATORIES INTERNATIONAL HOLDINGS LIMITED	+36.80%	2.24B
ELI LILLY AND COMPANY	+28.79%	673B
NOVO NORDISK A/S	+24.81%	551B
JOHNSON & JOHNSON	-7.64%	348B
MERCK & CO., INC.	+15.00%	317B
ABBVIE INC.	+5.99%	288B
ASTRAZENECA PLC	+2.47%	210B
NOVARTIS AG	-0.02%	204B
ROCHE HOLDING AG	-9.98%	195B
PFIZER, INC.	-11.71%	145B

Other Pharmaceuticals